Welcome to our dedicated page for Revance Therapeutics news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.
Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.
The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.
Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.
Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.
Revance Therapeutics, Inc. (RVNC) will announce its fourth quarter and full year 2022 financial results on February 28, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a corporate update. Interested participants can join by dialing (800) 715-9871 with conference ID: 1286316 or via the webcast available on their website. A replay will be accessible from February 28 until March 28, 2023. Revance is recognized for its innovative aesthetic and therapeutic solutions, including DAXXIFY® and a biosimilar collaboration with Viatris Inc.
Revance Therapeutics (RVNC) reports a strong start for its DAXXIFY® PrevU program, with approximately 400 practices participating and positive patient feedback. Preliminary Q4 2022 revenue from DAXXIFY® is estimated between $10.5 million and $11.5 million, while RHA® Collection revenue shows impressive growth, projected at $34 million to $35 million, a 45% year-over-year increase. Full-year 2022 RHA® revenue is expected between $106.5 million and $107.5 million. Revance maintains its operating expense guidance and ends the year with around $340 million in cash and equivalents.
Revance Therapeutics announced that the FDA has accepted its supplemental Biologics License Application for DAXXIFY® (DaxibotulinumtoxinA-lanm) aimed at treating cervical dystonia. The PDUFA date is set for August 19, 2023. This treatment, noted for its long-lasting effects, was evaluated in two pivotal phase 3 studies showing significant efficacy with a median duration of effect of 24 weeks. The market for muscle movement disorders, including cervical dystonia, is nearing $1 billion in the U.S., indicating substantial business potential for Revance.
Revance Therapeutics (NASDAQ: RVNC) announced its participation in the 34th Annual Piper Sandler Healthcare Conference from November 29 to December 1, 2022, in New York City. CEO Mark J. Foley will present on November 29 at 10:00 AM ET. The live audio webcast will be accessible on the company’s Investor Relations webpage and will remain available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic products and is known for offerings like DAXXIFY™ and the RHA® Collection. The company also collaborates with Viatris to develop a biosimilar to BOTOX®.
Nanostics Inc. announced the appointment of Aubrey Rankin to its Board of Directors, succeeding Reg Joseph as an independent director. Rankin brings extensive experience in MedTech and FinTech, having formerly served as President of Innovation at Revance (Nasdaq: RVNC), where he integrated HintMD's patient-provider platform. His expertise is expected to aid in the launch of Nanostics' lead prostate cancer diagnostic, ClarityDX Prostate®, which uses a neural network algorithm to assess cancer risk based on biomarkers. The company expressed gratitude to Joseph for his contributions.
Revance Therapeutics (Nasdaq: RVNC) announced its participation in the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. CFO Tobin Schilke will present on November 15 at 3:00 p.m. ET. Interested investors can access the live audio webcast via the company's Investor Relations page at www.revance.com. The replay will be available for 30 days post-event. Revance is focused on innovative aesthetic and therapeutic solutions, including DAXXIFY™ and collaborations for BOTOX® biosimilars.
Revance Therapeutics, Inc. (RVNC) announced FDA approval for DAXXIFY™ to treat glabellar lines, marking a significant milestone. Q3 revenue reached $29.0 million, up 47% year-over-year, with RHA® Collection revenue at $26.1 million, also up 43%. The company completed a $230 million follow-on offering, ending Q3 with $378.6 million in cash and equivalents. Revance submitted an sBLA for DAXXIFY™ for cervical dystonia with a PDUFA target date in 2023. The call for Q3 results is scheduled for November 8, 2022.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the publication of two peer-reviewed articles in the Aesthetic Surgery Journal, focusing on injection techniques for treating glabellar lines. The studies emphasize the importance of precise interactions to optimize aesthetic results, highlighting the influence of injection techniques on eyebrow positioning. The first article evaluates how subtle differences in injection affect outcomes, while the second presents a systematic assessment algorithm for personalized treatments. This reflects Revance's ongoing commitment to enhancing patient care and outcomes in aesthetic treatments.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A conference call and live webcast are scheduled for 4:30 p.m. ET the same day to discuss the results and provide updates on business and pipeline initiatives. Revance specializes in innovative aesthetic and therapeutic offerings, including the DAXXIFY™ injection and biosimilar development for BOTOX®. The call will be accessible via registration, with a replay available for 30 days post-call.
Revance Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the FDA for DAXXIFY™ to treat cervical dystonia, a painful condition affecting neck muscles. The application is based on the ASPEN Phase 3 clinical program, showcasing DAXXIFY’s median response duration of 24 weeks. The company anticipates a PDUFA target action date in 2023. Successful approval could position Revance in the nearly $1 billion U.S. muscle movement disorder market, significantly reducing treatment frequency for patients.
FAQ
What is the current stock price of Revance Therapeutics (RVNC)?
What is the market cap of Revance Therapeutics (RVNC)?
What does Revance Therapeutics, Inc. specialize in?
What is the TransMTS® peptide delivery system?
What are the main products of Revance Therapeutics?
What is RT001?
What are the business segments of Revance Therapeutics?
How does Revance's TransMTS technology benefit its products?
What is the significance of DaxibotulinumtoxinA?
What is the RHA Collection?
What is the HintMD platform?
How does Revance's Product segment contribute to its revenue?
